Skip to content
10-Q

Quarterly Report

Nabriva Therapeutics plc

0001558370-22-017402

← back to feed
Filed
Nov 10, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Oct 31, 2022 3.06M sh
Shares Diluted Q3 2022 · Sep 30, 2022 2.73M sh
Shares Diluted Q3 2022 · Sep 30, 2022 2.54M sh
Shares Diluted restated Q3 2022 · Sep 30, 2021 2.02M sh
Shares Diluted restated Q3 2022 · Sep 30, 2021 1.57M sh
Capex Q3 2022 · Sep 30, 2022 $202K
Capex Q3 2022 · Sep 30, 2021 $17K
Operating Cash Flow Q3 2022 · Sep 30, 2022 −$35.09M
Operating Cash Flow Q3 2022 · Sep 30, 2021 −$53.44M
Long Term Debt Q3 2022 · Sep 30, 2022 $399K
Long Term Debt Q3 2022 · Dec 31, 2021 $4.27M
Short Term Debt Q3 2022 · Sep 30, 2022 $5.73M
Short Term Debt Q3 2022 · Dec 31, 2021 $3.77M
Cash And Equivalents Q3 2022 · Sep 30, 2022 $14.65M
Cash And Equivalents Q3 2022 · Dec 31, 2021 $47.66M
Stockholders Equity Q3 2022 · Sep 30, 2022 $25.62M
Stockholders Equity Q3 2022 · Jun 30, 2022 $34.61M
Stockholders Equity Q3 2022 · Mar 31, 2022 $44.63M
Stockholders Equity Q3 2022 · Dec 31, 2021 $53.35M
Stockholders Equity Q3 2022 · Sep 30, 2021 $63.29M
Stockholders Equity Q3 2022 · Jun 30, 2021 $69.2M
Stockholders Equity Q3 2022 · Mar 31, 2021 $54.99M
Stockholders Equity Q3 2022 · Dec 31, 2020 $33.14M
Current Liabilities Q3 2022 · Sep 30, 2022 $21.64M
Current Liabilities Q3 2022 · Dec 31, 2021 $22.34M
Total Liabilities Q3 2022 · Sep 30, 2022 $22.62M
Total Liabilities Q3 2022 · Dec 31, 2021 $27.56M
Current Assets Q3 2022 · Sep 30, 2022 $47.56M
Current Assets Q3 2022 · Dec 31, 2021 $80.27M
Total Assets Q3 2022 · Sep 30, 2022 $48.24M
Total Assets Q3 2022 · Dec 31, 2021 $80.91M
Eps Diluted Q3 2022 · Sep 30, 2022 −$4.21
Eps Diluted Q3 2022 · Sep 30, 2022 −$13.55
Eps Diluted restated Q3 2022 · Sep 30, 2021 −$5.27
Eps Diluted restated Q3 2022 · Sep 30, 2021 −$23.17
Eps Basic Q3 2022 · Sep 30, 2022 −$4.21
Eps Basic Q3 2022 · Sep 30, 2022 −$13.55
Eps Basic restated Q3 2022 · Sep 30, 2021 −$5.27
Eps Basic restated Q3 2022 · Sep 30, 2021 −$23.17
Sga Expense Q3 2022 · Sep 30, 2022 $11.91M
Sga Expense Q3 2022 · Sep 30, 2022 $35.65M
Sga Expense Q3 2022 · Sep 30, 2021 $12.26M
Sga Expense Q3 2022 · Sep 30, 2021 $37.16M
Rd Expense Q3 2022 · Sep 30, 2022 $4.03M
Rd Expense Q3 2022 · Sep 30, 2022 $11.64M
Rd Expense Q3 2022 · Sep 30, 2021 $3.22M
Rd Expense Q3 2022 · Sep 30, 2021 $10.24M
Net Income Q3 2022 · Sep 30, 2022 −$11.51M
Net Income Q3 2022 · Sep 30, 2022 −$34.41M
Net Income Q3 2022 · Jun 30, 2022 −$11.07M
Net Income Q3 2022 · Mar 31, 2022 −$11.82M
Net Income Q3 2022 · Sep 30, 2021 −$10.65M
Net Income Q3 2022 · Sep 30, 2021 −$36.39M
Net Income Q3 2022 · Jun 30, 2021 −$11.75M
Net Income Q3 2022 · Mar 31, 2021 −$13.98M
Operating Income Q3 2022 · Sep 30, 2022 −$11.2M
Operating Income Q3 2022 · Sep 30, 2022 −$33.16M
Operating Income Q3 2022 · Sep 30, 2021 −$10.81M
Operating Income Q3 2022 · Sep 30, 2021 −$35.64M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $4.42M
Cost Of Revenue Q3 2022 · Sep 30, 2022 $12.23M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $4.2M
Cost Of Revenue Q3 2022 · Sep 30, 2021 $7.88M
Revenue Q3 2022 · Sep 30, 2022 $9.15M
Revenue Q3 2022 · Sep 30, 2022 $26.36M
Revenue Q3 2022 · Sep 30, 2021 $8.86M
Revenue Q3 2022 · Sep 30, 2021 $19.63M
Short Term Investments Q3 2022 · Dec 31, 2021 $16K